Regarding short term share movement, and short ter
Post# of 148168
Other CYDY forums are hyping up the probability and necessity that Cytodyn will be getting an EUA for Leronlimab for critical covid-19 patients any day now, most likely this upcoming week. But the common question is, how then, would they be able to recruit for the new 4 dose trial for critical patients?
What "great" news can Nader announce Tuesday other than an EUA or approval from another nation?
The other hot topic is the probability expecting another country to approve and start purchasing Leronlimab, especially Brazil and the Philipines, and also that just the anticipation of another nation approving will put pressure on our FDA to approve first?
Twitter is very active with comments, and many from doctors, stating that Janet Woodcock is negligent (and/or worse) in not granting an EUA.
Granting an EUA would "technically" need to be based upon merely 62 critical patients in our s/c trial, but being practical, Janet could consider our early eIND results, our m/m trial, and misc doctors success comments.
Now add in the numerous and increasing number of folks claiming the FDA is corrupt and influenced by big pharma. Yeah, but this is getting even more complex, because now our confidence in the MOA Science has increased even more, most folks believe data is 99% supporting Leronlimab.
Buy more? Hold? EUA soon? EUA in 12 weeks?